secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
CIK:        0001500198
Form:       8-K
Filed at:   2024-12-17T23:59:59+00:00
Accession:  0001213900-24-109529
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroOne FY2024 product revenue $3.5M (+77%); FY2025 guidance $8-10M (+132-190%)
--------------------------------------------------------------------------------

- Product revenue FY2024 $3.5M (+77% YoY); net loss $12.3M vs $11.9M prior year.
- FY2025 product revenue guidance $8-10M (+132-190%); gross margin 47-51% vs 31% in FY2024.
- Received $3M upfront from expanded Zimmer Biomet distribution agreement in Nov 2024; terminated $3M credit facility.
- Net loss Q4 $3.3M vs $3.1M; operating expenses down 12% to $3.0M in Q4.
- Nasdaq compliance: monitoring bid price until Jan 7, 2025; equity restored above $2.5M after Zimmer payment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1500198/000121390024109529/0001213900-24-109529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1500198/000121390024109529/ea0224944-8k_neuro.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-109529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer